Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Neurokine Pharmaceuticals Inc       CAC611561100

NEUROKINE PHARMACEUTICALS INC

SummaryNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Pivot Pharmaceuticals : Cannabinoid topical cream for treatment of Female Hypoactive Sexual Desire Disorder

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/28/2018 | 04:22am EDT

Pivot Pharmaceuticals Inc. has announced that it will file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and Clinical Trial Application (CTA) with Health Canada to begin human clinical trials of PVT-005, the Companys pharmaceutical drug candidate for the treatment of Female Hypoactive Sexual Desire Disorder (HSDD).

HSDD, the most common type of female sexual dysfunction (FSD), affects approximately 12 million women in the U.S. alone. The condition is characterised by a low sexual desire and marked distress which are not attributable to existing medical, pharmacologic, psychiatric, or relationship issues. Approximately 6 million pre-menopausal women meet the diagnosis for acquired, generalized HSDD.

Using the formulation and delivery platform technologies, the Company will develop and aim to commercialise a topical cream containing cannabinoids (PVT-N005) for perimenopausal, menopausal and post-menopausal women who have noticed a decline in sexual desire and response. While erectile dysfunction in men has been extensively researched, very little has been completed on female sexual dysfunction which can involve reduced sex drive, difficulty becoming aroused, vaginal dryness, lack of orgasm and decreased sexual satisfaction.

In vitro results from our contract research laboratory indicated that PVT-005 (1% CBD formulated) was highly bioavailable. Additional studies showed that the product did not cause any local irritation in an in-vivo model. We have also successfully conducted degradation and stability studies with the product candidate. As a result, we have selected a drug candidate for HSDD which we will move to IND and CTA filings with health authorities to conduct clinical trials in women. Our cGMP manufacturing partner, BioV Pharma Inc., will produce the clinical trial material made using our formulation technology, said Dr Joseph Borovsky, Pivots Executive Vice President, Product Development.

Pivots Chief Medical Officer, Dr Wolfgang Renz stated Given that our topical delivery system has previously shown to be safe and well tolerated when administered intravaginally in a clinical trial setting, we believe that we can deliver cannabinoids to target female sexual dysfunction, a large unmet medical need with a multi-billion dollar market. The use of a highly bioavailable and safe topical cannabinoid is a great option for treating this indication, avoiding the known side effects of existing therapeutics.

While men have had Viagra, Cialis, and Levitra to address their sexual dysfunction issues, finding a solution for FSD has been more complicated. The market for female sexual dysfunction drugs is believed to be larger than the market for male sexual dysfunction treatments since the percentage of women with FSD between the ages 18 and 59 is higher than that for men. The FSD market in the U.S. is estimated to exceed $4 billion with over 50 million potential sufferers.

(c) APS 2018. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEUROKINE PHARMACEUTICALS
05/21PIVOT PHARMACEUTICALS INC. : Unregistered Sale of Equity Securities (form 8-K)
AQ
05/21PIVOT PHARMACEUTICALS : Pharma Begins Production of 100,000 Units of CBD Solutio..
AQ
05/15PIVOT PHARMACEUTICALS : Pharma Announces Closing of C$11.533 million First Tranc..
AQ
05/03PIVOT PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
AQ
05/02PIVOT PHARMACEUTICALS : Pharma Issues Statement on California Operations
AQ
04/25PIVOT PHARMACEUTICALS : Pharma Engages Harris Bricken LLP for California Cannabi..
AQ
04/09PIVOT PHARMACEUTICALS : IIROC Trade Resumption - PVOT
AQ
04/08PIVOT PHARMACEUTICALS : Completes C$590,000 Non-Brokered Private Placement
AQ
04/08PIVOT PHARMACEUTICALS : IIROC Trading Halt - PVOT
AQ
04/03PIVOT PHARMACEUTICALS : IIROC Trade Resumption - PVOT
AQ
More news
Chart NEUROKINE PHARMACEUTICALS INC
Duration : Period :
Neurokine Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Patrick Charles Frankham President, CEO, Director & VP-Business Development
Joseph Borovsky Chairman
Moira Ong Chief Financial Officer
Wolfgang Renz Director & Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEUROKINE PHARMACEUTICALS INC0
GILEAD SCIENCES6.94%85 054
VERTEX PHARMACEUTICALS3.66%43 994
REGENERON PHARMACEUTICALS-16.32%33 671
GENMAB14.61%11 324
SAREPTA THERAPEUTICS INC10.73%8 961